ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Clinical phenotypes and outcomes of spinal cord stimulation in painful peripheral polyneuropathy: a cohort including diabetic, chemotherapy-induced, and idiopathic etiologies.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Chronic painful peripheral polyneuropathy (PPN) is a leading global cause of chronic pain and may arise from a wide range of etiologies. When pharmacological treatments fail to provide adequate pain relief, spinal cord stimulation (SCS) has demonstrated efficacy in selected subtypes. This study investigated the effectiveness of SCS in alleviating pain, neurological symptoms and signs, and other health-related outcomes in patients with diverse forms of PPN, including diabetic (DPN) and chemotherapy-induced (CIPN) peripheral neuropathies, and chronic idiopathic axonal polyneuropathy (CIAP). Methods: This prospective, single-center observational study included 30 patients with drug-refractory PPN (11 DPN, 8 CIPN, 9 CIAP, and 2 other etiologies: 1 amyloidosis and 1 Fabry disease). All patients were implanted with two percutaneous leads at T10-T11 targeting lower limbs; a cervical lead (C4-C7) when upper limb pain was present; and SCS system. Low-frequency (<100 Hz) sub-perception and/or supra-perception stimulation modalities were offered. Clinical outcomes were assessed at baseline and at 2, 4, 6, and 12 months post-implantation and included pain (VAS, SF-MPQ-2), neuropathic symptoms (NPSI), autonomic symptoms (SAS), neurological signs, and other health-related factors. Intraepidermal nerve fiber density (IENFD) was assessed at baseline and at 12 months. Results: Baseline evaluations demonstrated severe disease burden, with CIAP patients exhibiting more pain symptoms and DPN patients more neurologic deficits. SCS produced a significant and sustained reduction in pain intensity and symptoms (VAS from 8.6 to 2.0, SF-MPQ-2 from 115.5 to 23.0; Discussion: SCS was associated with substantial and durable improvements in pain, neuropathic and autonomic symptoms, and other wellbeing outcomes across multiple painful PPN etiologies. The IENFD results suggest that SCS may have some effects on small-fiber integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.